公开(公告)号：US20180117173A1

公开(公告)日：2018-05-03

申请号：US15573550

申请日：2016-05-19

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Valery KRIZHANOVSKY ,  Yossi OVADYA

IPC: A61K47/68 ,  C12N15/113 ,  C07K16/18 ,  A61P35/00 ,  A61K45/06

CPC classification number: A61K47/6843 ,  A61K45/06 ,  A61K47/6807 ,  A61K47/6849 ,  A61P35/00 ,  C07K16/18 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2310/3513

Abstract: A method of targeting a pharmaceutical agent to a senescent cell is disclosed. The method comprises administering the pharmaceutical agent to the subject, wherein said pharmaceutical agent is attached to an affinity moiety, said affinity moiety being capable of binding specifically to a polypeptide selected from the group consisting of HSP90B1, DNAJB4, PI4K2A, DBN1, PRKCSH, SPTBN1, NPM1, ITGA3 and a polypeptide set forth in Table 1. The targeting may be for therapeutics or diagnostics.

公开(公告)号：US20210038740A1

公开(公告)日：2021-02-11

申请号：US17075738

申请日：2020-10-21

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Valery KRIZHANOVSKY ,  Yossi OVADYA

IPC: A61K47/68 ,  A61P35/00 ,  A61K45/06 ,  C07K16/18 ,  C12N15/113

Abstract: A method of targeting a pharmaceutical agent to a senescent cell is disclosed. The method comprises administering the pharmaceutical agent to the subject, wherein said pharmaceutical agent is attached to an affinity moiety, said affinity moiety being capable of binding specifically to a polypeptide selected from the group consisting of HSP90B1, DNAJB4, PI4K2A, DBN1, PRKCSH, SPTBN1, NPM1, ITGA3 and a polypeptide set forth in Table 1. The targeting may be for therapeutics or diagnostics.

公开(公告)号：US20230094083A1

公开(公告)日：2023-03-30

申请号：US18062601

申请日：2022-12-07

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Valery KRIZHANOVSKY ,  Yossi OVADYA

IPC: C07K16/44 ,  A61P43/00

Abstract: Described herein are anti-human Grp94 antibodies. The antibodies may be used to target senescent cells. Thus, the anti-Grp94 antibodies would be useful in treating diseases and conditions associated with cellular senescence. The anti-Grp94 antibodies could target senescent cells in vivo. Therefore, the anti-Grp94 antibodies could be used to target senescent cells associated with age-related diseases in vivo.

公开(公告)号：US20180345047A1

公开(公告)日：2018-12-06

申请号：US15552506

申请日：2016-02-25

Applicant: Yeda Research and Development Co. Ltd. ,  Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Inventor： Valery KRIZHANOVSKY ,  Reut YOSEF ,  Noam PILPEL ,  Ittai BEN-PORATH ,  Liat DASSA ,  Ronit AMIEL-TOKARSKY

IPC: A61P17/14 ,  A61Q7/00 ,  A61K9/00

CPC classification number: A61Q7/00 ,  A61K8/606 ,  A61K31/11 ,  A61K31/34 ,  A61K31/404 ,  A61K31/635 ,  A61K31/713

Abstract: A method of promoting hair growth or reducing hair loss in a subject is disclosed. The method comprises contacting the scalp and skin region in which there is desire for hair growth of the subject with an effective amount of at least one agent which down-regulates an activity and/or an amount of a protein selected from the group consisting of p21, Bcl-xL and Bcl-w. Compositions capable of same are also disclosed.

公开(公告)号：US20160122758A1

公开(公告)日：2016-05-05

申请号：US14784312

申请日：2014-04-13

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Valery KRIZHANOVSKY ,  Noam PILPEL ,  Reut YOSEF

IPC: C12N15/113 ,  A61K9/00 ,  A61K31/635 ,  A61K45/06 ,  A61K38/17

CPC classification number: C12N15/113 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/06 ,  A61K31/4965 ,  A61K31/5377 ,  A61K31/635 ,  A61K31/713 ,  A61K38/1709 ,  A61K45/06 ,  C12N15/1135 ,  C12N2310/14 ,  C12N2320/31 ,  A61K2300/00

Abstract: A method of treating an inflammatory or fibrotic disease in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of an agent which down-regulates an activity and/or an amount of Bcl-xL and/or Bcl-w and/or p21, with the proviso that the inflammatory disease is not cancer.

Abstract translation: 公开了治疗受试者的炎性或纤维化疾病的方法。 该方法包括向受试者施用治疗有效量的下调Bcl-xL和/或Bcl-w和/或p21的活性和/或量的试剂，条件是炎性疾病不是癌症 。